StockData
Biohaven Ltd. logo

Biohaven Ltd. (BHVN) stock

BHVNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 1/30
$12.90−0.34 (-2.57%)

Close on Nov 18, 2026Market cap $1.95BP/E –Yield –

Biohaven operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Biohaven's operating cash flow for the twelve months ending Sep 30, 2026 was -$472.53M. For fiscal 2025 it was -$609.44M. The highest annual figure on record is -$75.96M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$609.44M–
FY2024Dec 31, 2024-$582.45M–
FY2023Dec 31, 2023-$331.73M–
FY2022Dec 31, 2022-$297.69M–
FY2021Dec 31, 2021-$145.84M–
FY2020Dec 31, 2020-$75.96M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$106.85M–
Q2 FY2026Jun 30, 2026-$85.10M–
Q1 FY2026Mar 31, 2026-$149.92M–
Q4 FY2025Dec 31, 2025-$130.66M–
Q3 FY2025Sep 30, 2025-$145.72M–
Q2 FY2025Jun 30, 2025-$167.94M–
Q1 FY2025Mar 31, 2025-$165.12M–
Q4 FY2024Dec 31, 2024-$170.74M–
Q3 FY2024Sep 30, 2024-$141.28M–
Q2 FY2024Jun 30, 2024-$167.80M–
Q1 FY2024Mar 31, 2024-$102.64M–
Q4 FY2023Dec 31, 2023-$114.88M–
Q3 FY2023Sep 30, 2023-$94.81M–
Q2 FY2023Jun 30, 2023-$44.39M–
Q1 FY2023Mar 31, 2023-$77.64M–
Q4 FY2022Dec 31, 2022-$75.41M–
Q3 FY2022Sep 30, 2022-$95.56M–
Q2 FY2022Jun 30, 2022-$67.89M–
Q1 FY2022Mar 31, 2022-$58.84M–
Q4 FY2021Dec 31, 2021-$33.06M–

More Biohaven figures

See a number that looks wrong?